The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels

Bibliography

• BOUSHEY CJ, BERESFORD SA, OMENN GS et al.: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JA/VIA (1995) 274(13):1049–1057.
   Google Scholar
• BRATTSTROM L, WILCKEN DE: and cardiovascular disease: cause or effect? Am. Clin. Nutr. (2000) 72:315–323.
   Web of Science ®Google Scholar
• UELAND PM, REFSUM H, BERESFORD SA et al.: The controversy over homocysteine and cardiovascular risk. Clin. Nutr. (2000) 72:324–332.
   Web of Science ®Google Scholar
• WALD NJ, LAW MR: A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. (2003) 326(7404):1419.
   PubMed Web of Science ®Google Scholar
• ASSMANN G, SCHULTE H, FUNKE H et al.: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Ear: Heart J. (1998) 19 (Suppl. M):M8–M14.
   Google Scholar
• JEPPESEN J, HEIN HO, SUADICANI P et al.: Triglyceride concentration and ischemic heart disease: an eight-year follow up in the Copenhagen Male Study. Circulation (1998) 97:1029–1036.
   PubMed Web of Science ®Google Scholar
• BROWN WV: Potential use of fenofibrate and fibric acid derivatives in the clinic. Am.j Med. (1987) 83:85–89.
   PubMed Web of Science ®Google Scholar
• FRUCHART JC, STAELS B, DURIEZ P: The role of fibric acids in atherosclerosis. Carr: Atherosclerosis Rep. (2001) 3:83–92.
   PubMedGoogle Scholar
• VAUGHAN CJ, GOTTO AM Jr, BASSON CT: The evolving role of statins in the management of atherosclerosis. J. Ain. Coll Cardiol (2000) 35:1–10.
   PubMed Web of Science ®Google Scholar
• ALTSCHUL R, HOFFER A, STEPHEN JD: Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. (1955) 54:558–559.
   PubMed Web of Science ®Google Scholar
• KNOPP RH: Drug treatment of lipid disorders. N Engl. J. Med. (1999)
   Google Scholar
• •Comprehensive overview of the treatment of dyslipidaemias.
   Google Scholar
• KIRCHGASSLER KU, SCHMITZ H, BACH G: Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200 mg in a drug-monitoring programme involving 9884 patients with
   Google Scholar
• KORNITZER M, DRAMAIX M, VANDENBROEK MD et al.: and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis (1994) 110 (Suppl.):S49–S54.
   Google Scholar
• MCCULLY KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Pathol (1969) 56(1):111–128.
   Google Scholar
• MCCULLY KS, WILSON RB: Homocysteine theory of arteriosclerosis. Atherosclerosis (1975) 22(2):215–227.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, LONN E, GENEST J Jr, HANKEY G, YUSUF S: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. (1999) 131:363–375.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, MALINOW MR, WILLETT WC et al: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA (1992) 268(7):877–881.
   PubMed Web of Science ®Google Scholar
• NYGARD O, NORDREHAUG JE, REFSUM H, UELAND PM, M, VOLLSET SE: homocysteine levels and mortality in patients with coronary artery disease. Engl. J. Med. (1997) 337(4):230–236.
   PubMed Web of Science ®Google Scholar
• FOLSOM AR, NIETO FJ, PG et al: study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. (1998) 98(3):204–210. STUDIES COLLABORATION: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JA MA (2002) 288(16):2015–2022.-analysis of studies on homocysteine as a risk factor for coronary heart disease. It provides a detailed analysis of the significance of homocysteine and an excellent overview of relevant studies.
   Google Scholar
• SCHNYDER G, ROFFI M, PIN R et al:Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med. (2001) 345:1593–1600.
   PubMed Web of Science ®Google Scholar
• WELCH GN, LOSCALZO J: Homocysteine and atherothrombosis. N. Engl. J. Med. (1998) 338:1042–1050.
   PubMed Web of Science ®Google Scholar
• THAMBYRAJAH J, TOWNEND JN: Homocysteine and atherothrombosis - mechanisms for injury. Eui: Heart J. (2000) 21:967–974.
   PubMed Web of Science ®Google Scholar
• TAWAKOL A, OMLAND T, M et al.:(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation (1997) 95:1119–1121.
   PubMed Web of Science ®Google Scholar
• CHAMBERS JC, OBEID OA, JS: Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler. Thrornb. Vase. Biol. (1999) 19:2922–2927.
   PubMed Web of Science ®Google Scholar
• THAMBYRAJAH J, LANDRAY MJ, JONES HJ et al.: randomized double-blind-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. Am. Coll. Cardiol. (2001) 37: 1858-1863.
   Google Scholar
• BOGER RH, LENTZ SR, BODE-BOGER SM et al: of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin. Sci. (fond.) (2001) 100:161–167.
   PubMed Web of Science ®Google Scholar
• NAPPO F, DE ROSA N, MARFELLA R et al.: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA (1999) 281:2113–2118.
   PubMed Web of Science ®Google Scholar
• SUNDER-PLASSMANN G, M: Genetic determinants of the homocysteine level. Kidney Int. (2003) 84(Suppl.):S141–S144.
   Google Scholar
• KLERK M, VERHOEF P, CLARKE R, BLOM HJ, KOK FJ, SCHOUTEN EG; MTHFR STUDIES GROUP: 677C-> T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA (2002) 288(16):2023–2031.
   PubMed Web of Science ®Google Scholar
• SELHUB J, JACQUES PF, WILSON PW et al.: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 270:2693–2698.
   PubMed Web of Science ®Google Scholar
• SCHNEEDE J, REFSUM H, UELAND PM:Biological and environmental determinants of plasma homocysteine. Sernin. Thromb. Hemost. (2000) 26(3):263–279.
   PubMed Web of Science ®Google Scholar
• WOLLESEN F, BRATTSTROM L, REFSUM H, UELAND PM, L, BERNE C: total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. (1999) 55:1028–1035.
   PubMed Web of Science ®Google Scholar
• BRATTSTROM L, LINDGREN A, ISRAELSSON B et al.: Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. Intern. Med. (1994) 236:633–641.
   Web of Science ®Google Scholar
• DIERKES J, JECKEL A, AMBROSCH A, WESTPHAL S, LULEY C, BOEING H: Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. (2001) 50:640–645.
   Google Scholar
• NORLUND L, GRUBB A, FEX G et al.:The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin. Chem. Lab. Med. (1998) 36:175–178.
   PubMed Web of Science ®Google Scholar
• DESOUZA C, KEEBLER M, DB et al.: Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs (2002) 62:605–616.
   PubMed Web of Science ®Google Scholar
• •Overview on additional drugs that affect homocysteine.
   Google Scholar
• DE LORGERIL M, SALEN P, F et al.: Lipid-lowering drugs and homocysteine. Lancet (1999) 353:209–210.
   PubMed Web of Science ®Google Scholar
• DIERKES J, WESTPHAL S, LULEY C: Serum homocysteine increases after therapy with fenofibrate or bezafibrate. (1999) 354:219–220.
   Google Scholar
• GIRAL P, BRUCKERT E, JACOB N et al:Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis (2001) 154:421–427.
   Google Scholar
• BISSONNETTE R, TREACY E, ROZEN R et al: Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis (2001) 155:455–462.
   PubMed Web of Science ®Google Scholar
• LANDRAY MJ, TOWNEND JN, MARTIN S et al.: Lipid-lowering drugs and homocysteine. Lancet (1999) 353:1974–1975.
   PubMed Web of Science ®Google Scholar
• JONKERS IJ, DE MAN FH, ONKENHOUT W, DER LAARSE A, SMELT AH: Implication of fibrate therapy for homocysteine. Lancet (1999) 354:1208.
   PubMedGoogle Scholar
• HARATS D, YODFAT O, DOOLMAN R et al.: Homocysteine elevation with fibrates: is it a class effect? Isr. Med. Assoc. J. (2001) 3:243–246.
   Web of Science ®Google Scholar
• WESTPHAL S, DIERKES J, LULEY C: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet (2001) 358:39–40.
   PubMed Web of Science ®Google Scholar
• MELENOVSKY V, STULC T, KOZICH V et al.: Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. Am. Heart J. (2003) 146(1):110.
   PubMedGoogle Scholar
• DIERKES J, WESTPHAL S, KUNSTMANN S et al: supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis (2001) 158:161–164.
   PubMed Web of Science ®Google Scholar
• •Study on the effect of vitamins on the fibrate-induced increase of homocysteine, including a discussion of the safety and efficacy of vitamin supplementation.
   Google Scholar
• MAYER O Jr, SIMON J, HOLUBEC L, PIKNER R, SUBRT I: Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Earl-. Clin. Pharmacol. (2003). Epublished ahead of print.
   Google Scholar
• LIPSCOMBE J, LEWIS GF, CATTRAN D et al: Deterioration in renal function associated with fibrate therapy. Clin. Nephrol. (2001) 55:39–44.
   PubMed Web of Science ®Google Scholar
• BROEDERS N, KNOOP C, M et al.:-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol. Dial. Transplant. (2000) 15:1993–1999.
   Web of Science ®Google Scholar
• HOTTELART C, EL ESPER N, ROSE F, ACHARD JM, FOURNIER A: increases creatininemia by increasing metabolic production of creatinine. Nephron (2002) 92(3):536–541.
   PubMed Web of Science ®Google Scholar
• WILSON MW, LAY LT, CHOW CK et al:Altered hepatic eicosanoid concentrations in rats treated with the percodsome proliferators ciprofibrate and perfluorodecanoic acid. Arch. Toxicol. (1995) 69:491–497.
   PubMed Web of Science ®Google Scholar
• DEVUYST O, GOFFIN E, PIRSON Y et al.: Creatinine rise after fibrate therapy in renal graft recipients. Lancet (1993) 341:840.
   PubMed Web of Science ®Google Scholar
• PANDERS E, ERLANDSEN EJ: cystatin C as an endogenous marker of the renal function - a review. Clin. Chem. Lab. Med. (1999) 37(4):389–395.
   PubMed Web of Science ®Google Scholar
• KHAN KNM et al.: Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. (2002) 61:1210–1219.
   PubMed Web of Science ®Google Scholar
• LEGENDRE C, CAUSSE E, CHAPUT E, SALVAYRE R, PINEAU T, EDGAR AD: Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARa-mediated effect. Biochem. Biophys. Res. Commun. (2002) 295(5):1052–1056.
   PubMed Web of Science ®Google Scholar
• •Animal study on the potential mechanism of homocysteine increase by fenofibrate.
   Google Scholar
• HOTTELART C, EL ESPER N, JM, PRUNA A, FOURNIER A: [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. Nephrologie (1999) 20:41-44. French.
   Google Scholar
• DEIGHAN CJ, CASLAKE MJ, MCCONNELL M,-JONES JM, PACKARD CJ: Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J. Am. Soc. Nephrol. (2001) 12(2):341–348.
   PubMed Web of Science ®Google Scholar
• STEAD LM, AU KP, JACOBS RL et al: Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. J. Physiol. Endocrinol. Metab. (2001) 28:E1095–E1100.
   Google Scholar
• STEENGE GR, VERHOEF P, GREENHAFF PL: The effect of creatine and resistance training on plasma homocysteine concentration in healthy volunteers. Arch. Intern. Med. (2001) 161:1455–1456.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, HULTBERG B, NILSSON-EHLE p, THYSELL H: effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand. Clin. Lab. Invest. (1996) 56(1):41–46.
   PubMed Web of Science ®Google Scholar
• CHAMBERS JC, UELAND PM, WRIGHT M, DORE CJ, REFSUM H, KOONER JS: Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ. Res. (2001) 89 (2) :187–192.
   PubMed Web of Science ®Google Scholar
• BASU TK, MANN S: B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects.: (1997) 127(1):117–121.
   Google Scholar
• UELAND PM, REFSUM H, STABLER SP, MALINOW MR, ANDERSSON A, ALLEN RH: homocysteine in plasma or serum: methods and clinical applications. Chem. (1993) 39 (9) :1764–1779.
   Google Scholar
• NO AUTHORS LISTED: blood homocysteine with folic acid based supplements:-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. Br. Med. (1998) 316:894–898.
   Google Scholar
• RIDKER PM, SHIH J, COOK TJ et al; AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY (AFCAPS/TEXCAPS) INVESTIGATORS: Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. (2002) 105(15):1776–1779.
   Google Scholar
• LOTTJOHANN D, SIGIT JI, S et al.: High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia. Atherosclerosis (2001) 155:265–266.
   PubMedGoogle Scholar
• MACMAHON M, KIRKPATRICK C, CUMMINGS CE et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. (2000) 10:195–203.
   PubMed Web of Science ®Google Scholar
• GARG R, MALINOW M, M et al.: Niacin treatment plasma homocyst(e)ine levels. Am. Heart (1999) 138:1082–1087.
   PubMed Web of Science ®Google Scholar
• WANG W, BASINGER A, NEESE RA et al.: Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. j Physiol. Endocrinol. Metab. (2001) 280:E540–E547.
   PubMed Web of Science ®Google Scholar
• MUDD SH, POOLE JR: Labile methyl balances for normal humans on various dietary regimens. Metabolism (1975) 24:721–735.
   PubMed Web of Science ®Google Scholar
• ANDERSON JL, MUHLESTEIN JB, HORNE BD et al.: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. (2000) 102:1227–1232.
   Google Scholar
• SUNDER-PLASSMANN G, M: Pathophysiology and clinical importance of hyperhomocysteinemia: intervention studies. Miner. Electrolyte Metab. (1999) 25:286–290.
   PubMedGoogle Scholar
• ROBINS SJ, COLLINS D, WITTES JT et al: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 285:1585–1591.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl. I Med. (1987) 317:1237–1245.
   Google Scholar
• NO AUTHORS LISTED: of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357:905–910.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: prevention by raising cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102 (1) :21–27.
   PubMed Web of Science ®Google Scholar
• CAPECCHI PL, LAZZERINI PE, MACCHERINI M et al.: Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients. Transplant. Proc. (2002) 34(4):1273–1274.
   PubMed Web of Science ®Google Scholar
• HAAK E, ABLETSHAUSER C, WEBER S et al.: Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis (2001) 155 (2):395–401.
   PubMed Web of Science ®Google Scholar
• MELENOVSKY V, MALIK J, D et al.: Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart]. (2002) 144(4):E6.
   PubMedGoogle Scholar
• MILIONIS HJ, PAPAKOSTAS, A et al.: Comparative effects of atorvastatin, simvastatin and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. I Clin. Pharmacol. (2003) 43:825–830.
   PubMed Web of Science ®Google Scholar
• SASAKI S, KUWAHARA N, KUNITOMO K et al.: of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol. (2002) 89 (4):386–389.
   PubMed Web of Science ®Google Scholar
• STULC T, MELENOVSKY V, GRAUOVA B et al.: supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition (2001) 17:721–723.
   PubMed Web of Science ®Google Scholar
• MALIK J, MELENOVSKY V, WICHTERLE D: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res. (2001) 52 (2) : 290–298.
   PubMed Web of Science ®Google Scholar